Biotech Values

[DewDiligence]

>>DD, was that you getting nowhere with questions about the precedent for using historical control in study design?<<

Indeed it was, and I was not happy with the longwinded non-answer.

However, I think I hit paydirt with my follow-up question on pooling of the European and U.S. data. When Cox agreed that the U.S. trial’s active arm will effectively contain 31 patients, my spirits brightened considerably.

What’s your take?

p.s. I was happy enough with the CC to add a few shares even though I probably shouldn't have.